01/10/2017 - 2:15pm

Egalet said Arymo ER is the first drug approved using its proprietary Guardian Technology, which works to deter abuse and prevent the tablets from being manipulated for abuse or misuse. 

01/09/2017 - 2:19pm

Johnson and Johnson worldwide chairman, pharmaceuticals, Joaquin  Duato will be the next board chairman of PhRMA. 

01/06/2017 - 3:15pm

The number of drugs the FDA approved last year, 22, is less than half of the 45 approved in 2015 and lower than the average of the last 10 years of approvals, which is 29. 

01/06/2017 - 1:57pm
This is the fifth approved indication for Lucentis. 
01/06/2017 - 1:21pm

U.S. District Court Judge Sue Robinson on Thursday issued an injunction on the sale of Praluent, a PCSK9 inhibitor from Sanofi and Regeneron. Amgen, maker of another PCSK9 inhibitor Repatha, filed the request for the injunction in 2016.

01/05/2017 - 10:08am

FHC's new chief commercial officer will be responsible for all sales and marketing activities, with the goal of coordinating prelaunch, launch and sales and marketing activities.

01/04/2017 - 2:00pm

Dr. Jay Markowitz will work with other scientific and development leaders to evaluate the company’s portfolio evaluation and decision making while assessing external opportunities. 

01/04/2017 - 1:35pm

The drug, approved by the Food and Drug Administration in November, is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 

01/03/2017 - 2:36pm
Forbes is reporting that the Food and Drug Administration’s approval of 22 new drugs in 2016 (down from 51 in 2015) could have big implications for the future of innovation in the pharmaceutical space. The report notes that research spending is growing, but there are practical difficulties to translate innovation into products as R&D returns decline  — and the report suggests overcoming that difficulty could mean rethinking a lot. (Forbes)